Haemonetics SVP receives RSU grant, shares withheld for tax

Haemonetics Corp senior vice president of human resources Laurie A. Miller reported routine equity compensation activity involving company common stock.

Rhea-AI Filing Summary

Haemonetics Corp senior vice president of human resources Laurie A. Miller reported routine equity compensation activity involving company common stock. She received a grant of 13,323 shares valued at zero cost to her, reflecting the vesting or award of restricted stock units under the company’s long-term incentive plan.

In a related move, 948 shares at $56.29 each were withheld to cover tax obligations tied to the RSU vesting, a non-market transaction rather than an open-market sale. After these transactions, she directly holds 41,300 shares of Haemonetics common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Miller Laurie A.

Role SVP, Human Resources

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	948	$56.29	$53K
Grant/Award	Common Stock	13,323	$0.00	$0.00

Holdings After Transaction: Common Stock — 41,300 shares (Direct)

Footnotes (4)

1. F1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
2. F2. This number includes unvested RSUs previously reported.
3. F3. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
4. F4. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Key Figures

RSU shares granted: 13,323 shares Shares withheld for taxes: 948 shares Tax withholding price: $56.29 per share +2 more

5 metrics

RSU shares granted 13,323 shares Common stock grant/award on May 15, 2026

Shares withheld for taxes 948 shares Tax withholding on RSU vesting at $56.29 per share

Tax withholding price $56.29 per share Value used for 948 withheld shares

Shares held after transactions 27,977 shares Direct common stock holdings following Form 4 activity

Shares after grant before withholding 41,300 shares Total common shares directly held after RSU grant, prior to withholding

Key Terms

restricted stock units, RSUs, tax obligations, Long-Term Incentive Compensation Plan, +1 more

5 terms

restricted stock units financial

"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"This number includes unvested RSUs previously reported."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

tax obligations financial

"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units"

Long-Term Incentive Compensation Plan financial

"issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"

contingent right financial

"Each RSU represents a contingent right to receive one (1) share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Haemonetics (HAE) report for Laurie A. Miller?

Haemonetics reported that Laurie A. Miller received a grant of 13,323 shares of common stock as part of her equity compensation. In connection with RSU vesting, 948 shares were withheld at $56.29 per share to satisfy tax obligations, leaving her with 27,977 shares.

Was Laurie A. Miller’s Form 4 transaction in Haemonetics (HAE) an open-market trade?

No, the Form 4 shows compensation-related activity, not open-market trading. She received 13,323 shares from an RSU award at no cost, and 948 shares were withheld at $56.29 each solely to cover tax obligations from the vesting, not sold in the market.

How many Haemonetics (HAE) shares does Laurie A. Miller hold after this Form 4?

Following the reported RSU grant and tax withholding, Laurie A. Miller directly holds 27,977 shares of Haemonetics common stock. This figure reflects the net position after receiving 13,323 shares and having 948 shares withheld to meet related tax obligations on vesting.

What type of equity award did Laurie A. Miller receive from Haemonetics (HAE)?

She received restricted stock units (RSUs) under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. Each RSU represents a contingent right to receive one share of common stock as it vests over a three-year schedule in annual installments.

How are Laurie A. Miller’s RSUs in Haemonetics (HAE) scheduled to vest?

Her RSUs vest over three annual installments. Forty percent of the award vests on the first anniversary of the grant date, another forty percent on the second anniversary, and the remaining twenty percent on the third anniversary, delivering common shares upon each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 05:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Laurie A.

(Last) (First) (Middle)

125 SUMMER STREET

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Human Resources

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		F		948(1)	D	$56.29	27,977(2)	D
Common Stock	05/15/2026		A		13,323(3)	A	(4)	41,300(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

2. This number includes unvested RSUs previously reported.

3. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

4. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

	/s/ Thomas V. Powers, attorney-in-fact for Ms. Miller	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)